alpha-Thujone is a monoterpene ketone best known as a major constituent of sage, wormwood, cedar leaf thuja, and related oils. Compared with many archive constituents, its literature base is relatively strong for mechanism and safety: live sources support GABA-related neuroactivity, additional 5-HT3 receptor modulation, and established regulatory concern at higher exposures. That makes alpha-thujone important for identity and toxicology context, but not a constituent to describe with casual wellness claims.
Chemical identity and composition
PubChem lists alpha-thujone under the broader thujone record with formula C10H16O and IUPAC name (1S,4R,5R)-4-methyl-1-propan-2-ylbicyclo[3.1.0]hexan-3-one. In the local archive it is a major chemotype marker in Dalmatian/common sage at roughly 18-43% by ISO-linked references, cedar leaf thuja around 48.7-51.5%, and a smaller marker in blue yarrow around 2.8%, which fits its reputation as a high-impact but safety-sensitive monoterpene ketone.
Aroma and practical use
- Use the recorded sharp, herbal, camphoraceous, medicinal descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 2000 PNAS paper reported that alpha-thujone is a rapid-acting and readily detoxified modulator of the GABA-gated chloride channel.
A 2000 PNAS paper reported that alpha-thujone is a rapid-acting and readily detoxified modulator of the GABA-gated chloride channel.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
A 2004 receptor study found that alpha-thujone reduced 5-HT3 receptor activity through an effect on the desensitized state of the receptor.
A 2004 receptor study found that alpha-thujone reduced 5-HT3 receptor activity through an effect on the desensitized state of the receptor.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
A 2012 electrophysiology study reported that alpha-thujone reduced miniature inhibitory postsynaptic current frequency and amplitude, indicating both pre- and postsynaptic GABAergic effects.
A 2012 electrophysiology study reported that alpha-thujone reduced miniature inhibitory postsynaptic current frequency and amplitude, indicating both pre- and postsynaptic GABAergic effects.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
A 2014 chick study reported similar anxiogenic-like effects for central alpha- and beta-thujone, with differential modulation at GABAA receptors.
A 2014 chick study reported similar anxiogenic-like effects for central alpha- and beta-thujone, with differential modulation at GABAA receptors.
This experimental finding does not establish benefit, dose or safety in people using this blend.
National Toxicology Program studies concluded that alpha,beta-thujone caused preputial gland cancers in male rats, with additional tumor findings discussed for male rat adrenal glands.
National Toxicology Program studies concluded that alpha,beta-thujone caused preputial gland cancers in male rats, with additional tumor findings discussed for male rat adrenal glands.
This experimental finding does not establish benefit, dose or safety in people using this blend.
Use concerns and concentration limits
Sensitization concernNot assessed
Not assessed in the available record.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot assessed
Not assessed in the available record.
Penetration enhancementNot assessed
Not assessed in the available record.
A recorded constituent reference, not a recommended oil dilution. Product category, source applicability and all contributing oils must be checked before use.
unverified reference · No source provenance attachedEMA's public statement on thujone-containing herbal medicinal products recommends maximum daily thujone intakes and treats thujone as a constituent requiring explicit exposure control.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
No direct public citation is attached to this entry.
The main toxicology concern in the located literature is neurotoxicity at higher exposures, especially dose-related excitation, tremor, and convulsant risk linked to GABAergic interference.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
No direct public citation is attached to this entry.
Because alpha-thujone is a restricted and safety-sensitive constituent, constituent-led marketing should avoid implying routine calming, mood, digestive, or therapeutic benefit from thujone-rich oils.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
gaba a receptor modulation
The best-supported mechanism in the located literature is modulation of the GABA-gated chloride channel, which helps explain dose-related excitation and convulsant risk.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
five ht3 receptor inhibition
An additional receptor-level finding is reduced 5-HT3 receptor activity, indicating alpha-thujone is not limited to a single neuropharmacology target.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (5)
- Although the mechanism and toxicology literature is stronger than average, most direct alpha-thujone evidence is still preclinical rather than clinical.
- Many real-world exposure discussions concern mixed alpha,beta-thujone rather than alpha-thujone alone.
- Archive copy should emphasize safety and compositional context, not present alpha-thujone as a wellness-active ingredient.
- The numeric dermal reference lacks source provenance; a verified flag alone is insufficient.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.